Mitral paravalvular leaks are relatively common after surgical mitral replacement, with an incidence of 7%-17%. Most of these are subclinical leaks, a mere echocardiogram finding, but about 3% of patients can develop heart failure, hemolysis, or a combination of both, thus requiring a new intervention. For symptomatic patients, new surgery has been the traditional treatment<a href="https://solaci.org/en/2018/02/19/surgical-or-percutaneous-management-of-mitral-leak/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Transcatheter mitral valve repair with MitraClip has shown good results in symptomatic patients with extreme surgical risk in different studies. However, its “real world” benefits have not been studied in depth due to how complex this strategy is compared with other usual procedures. This study analyzed 2952 patients who underwent mitral<a href="https://solaci.org/en/2017/11/10/mitral-valve-repair-with-mitraclip-is-safe-in-high-risk-patients/" title="Read more" >...</a>
Courtesy of SBHCI. Two new transcatheter treatments for severe or massive functional tricuspid regurgitation have showed good results at 30 days, according to their feasibility studies. The long-forgotten tricuspid valve has been gaining more attention with research linking tricuspid regurgitation to an increase in mortality. Early studies used devices originally designed for the mitral or<a href="https://solaci.org/en/2017/11/06/tct-2017-the-tri-repair-and-the-forma-trials-new-devices-for-the-forgotten-valve/" title="Read more" >...</a>
Courtesy of the SBHCI. Intrepid is a 43-, 46-, and 50-mm nitinol self-expanding valve with bovine pericardial leaflets that is placed using a transapical delivery system with a 35-Fr access. This pilot study enrolled 50 patients with severe mitral regurgitation who were symptomatic and at a high surgical risk, or in whom surgery was contraindicated. Read<a href="https://solaci.org/en/2017/11/03/tct-2017-intrepid-mitral-replacement-with-a-self-expanding-device/" title="Read more" >...</a>
Paravalvular leak is complication derived from incomplete sealing between the implanted prosthesis and the native annulus, which occurs in 5% of all patients who undergo mitral valve replacement and 10% of those who undergo transcatheter aortic valve replacement. This is the most frequent non-structural valve dysfunction. While mild leaks can be asymptomatic, moderate to severe<a href="https://solaci.org/en/2017/10/12/transcatheter-reduction-or-surgery-for-paravalvular-leak-repair/" title="Read more" >...</a>
This new device offers the advantage of a lower frame height, which reduces the chance of coronary occlusion. The delivery system is totally motorized and the valve can be repositioned. In addition, the sheath is “14 F” for all valve sizes (23, 26 and 29mm). 203 patients were included, all with severe aortic stenosis<a href="https://solaci.org/en/2017/05/25/centera-results-of-the-new-self-expandable-valve/" title="Read more" >...</a>
Current surgical and medical treatment options for severe tricuspid regurgitation are extremely limited. However, this historically forgotten valve seems to have the option of transcatheter repair, nowadays. This observational study assessed the safety and feasibility of the MitraClip system for patients with severe chronic tricuspid regurgitation. All patients presented severe tricuspid regurgitation and<a href="https://solaci.org/en/2017/04/27/tricuspid-valve-repair-with-the-mitraclip-technique/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Aortic valve calcification and mitral annular calcification have the same etiology and are frequently present in high-risk patients undergoing transcatheter aortic valve replacement (TAVR). The implications of mitral annular calcification for patients undergoing TAVR has not been entirely clarified yet. The study examined 782 patients with severe aortic stenosis who underwent<a href="https://solaci.org/en/2017/02/14/tavr-reasons-to-consider-mitral-annular-calcification/" title="Read more" >...</a>
Both surgical and medical treatment options for functional mitral regurgitation are limited. The Cardioband system (Valtech Cardio, OrYehuda, Israel) is a new transvenous, transseptal direct mitral annuloplasty device. This work studied the safety and efficacy of this new device 6 months after implantation. Thirty-one patients with moderate to severe mitral regurgitation associated with severe impairment of the left systolic ventricular<a href="https://solaci.org/en/2017/01/18/mitral-annuloplasty-with-a-cardioband-device-effective-in-functional-mitral-regurgitation/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. This study sought to analyze the clinical impact and the level of improvement of mitral regurgitation (MR) in patients who receive a transcatheter aortic valve replacement (TAVR), and to find potential candidates for double valve repair with percutaneous techniques. Of 1.110 patients included, 177 (15.9%) suffered from severe pre-TAVR mitral<a href="https://solaci.org/en/2016/08/16/pre-tavi-mitral-regurgitation-is-associated-with-higher-mortality/" title="Read more" >...</a>